| 131.07 0.59 (0.45%) | 07-24 16:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 153.87 | 1-year : | 179.72 |
| Resists | First : | 131.74 | Second : | 153.87 |
| Pivot price | 126.23 |
|||
| Supports | First : | 119.27 | Second : | 111.56 |
| MAs | MA(5) : | 127.94 |
MA(20) : | 126.75 |
| MA(100) : | 117.94 |
MA(250) : | 103.48 |
|
| MACD | MACD : | 2.2 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 82.2 |
D(3) : | 67.2 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 131.74 | Low : | 74.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRK ] has closed below upper band by 4.8%. Bollinger Bands are 2.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 131.72 - 132.18 | 132.18 - 132.6 |
| Low: | 128.9 - 129.5 | 129.5 - 130.05 |
| Close: | 130.13 - 130.96 | 130.96 - 131.72 |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Sat, 25 Jul 2026
Upper Gwynedd: Merck working on new manufacturing facility - North Penn Now
Fri, 24 Jul 2026
Merck licenses experimental HIV pill to generic makers in 129 countries - Reuters
Fri, 24 Jul 2026
Merck stages expanded access to monthly HIV PrEP pill ahead of approval - Fierce Pharma
Fri, 24 Jul 2026
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal - Endpoints News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,470 (M) |
| Shares Float | 2,470 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 82.2 (%) |
| Shares Short | 31,380 (K) |
| Shares Short P.Month | 30,550 (K) |
| EPS | 3.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.57 |
| Profit Margin | 13.5 % |
| Operating Margin | 38.5 % |
| Return on Assets (ttm) | 12.5 % |
| Return on Equity (ttm) | 18.9 % |
| Qtrly Rev. Growth | 4.9 % |
| Gross Profit (p.s.) | 20.42 |
| Sales Per Share | 26.62 |
| EBITDA (p.s.) | 11.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 17,890 (M) |
| Levered Free Cash Flow | 14,050 (M) |
| PE Ratio | 36.92 |
| PEG Ratio | 6.2 |
| Price to Book value | 7.05 |
| Price to Sales | 4.92 |
| Price to Cash Flow | 18.09 |
| Dividend | 0.85 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|